|
|
|
By Anna Rose Welch, Editorial & Community Director, Advancing RNA | I had the chance to sit down with ParcelBio’s CEO David Weinberg to learn more about the emerging market dynamics in the in vivo CAR-T space, with a particular focus on the challenges facing RNA biotechs looking to navigate this up-and-coming therapeutic class. | |
|
|
|
By Jyotsna Jajula, Wayne State University | An RNA therapeutic can generate a strong molecular signal without producing the intended biological function. Let's look at how best to predict whether the RNA has completed its task. | |
|
|
|
By Advancing RNA Live | In this clip, Advancing RNA Live speakers Elaine Peters, Philippe Talaga, and Ilya Shestopalov advocate for an orthogonal approach as we strive to better understand our LNP QAs — with particular attention paid to particle size. | |
|
|
|
A conversation with Art Krieg, Zola Therapeutics | Krieg believes the answer lies in a deeper understanding of innate immune biology and the design of RNA/DNA hybrid mimics of viral RNA and DNA that are detected by innate immune receptors. | |
|
|
|
| From LAL To rFC: The Evolution Of Endotoxin Testing | Application Note | By Thomas Lehman, Ph.D., and Tessa Patton, Eurofins | Protect patient safety and ensure regulatory compliance by implementing sensitive, reliable bacterial endotoxin testing as a critical component of pharmaceutical quality assurance. |
|
|
|
|
|
|
|
|
|
|
.png){kind=logo}
